Murali Janakiram, M.D., M.S., is a strong believer in City of Hope’s approach to treating the whole person, personalizing care to address each patient’s individual needs. He finds great satisfaction in helping his patients and is excited about contributing to scientific advances that will define the future of cancer care.

Fluent in Tamil, Dr. Janakiram earned his medical degree from Madras Medical College in Chennai, India. He completed an internship and residency in internal medicine at Case Western Reserve University and a fellowship in oncology/hematology at the Albert Einstein College of Medicine, where he also received a master's degree in clinical research. Before joining City of Hope, he was an assistant professor at the University of Minnesota. He made significant contributions to T cell lymphoma and especially for a rare subtype adult T cell leukemia lymphoma.

A clinical trialist and investigator with over 50 peer-reviewed publications, reviews and book chapters, Dr. Janakiram at City of Hope studies cellular and immune based therapies [CART, NK cell] in myeloma. His interests are in developing risk-based approaches for the treatment of multiple myeloma. “Every person is different and I believe individualizing treatment according to physical and social circumstances will result in the best outcomes.”